Kornimate/medical-research-clean huggingface dataset:
effect of probiotic on constipation in patients with parkinson's disease

Conditions: Parkinson Disease; Constipation

Summary: the aim of the study is to collect data for the assessment of the lactobacillus casei dg (enterolactis ®duo) effect on constipation and on neuropsychological performance

the aim of the study is to collect data for the assessment of the lactobacillus casei dg (enterolactis® duo) effect on overall abdominal pain, bowel movements and other abdominal symptoms and on neuropsychological performance in patients with parkinson's disease. the investigators suppose that, due to the immunomodulatory action of probiotics, overall neuropsychological function will improve as well as due also to prebiotic abdominal symptoms will decrease following consumption of lactobacillus casei dg (enterolactis® duo).

Eligibility criteria:
inclusion criteria: * a positive diagnosis of functional constipation or irritable bowel syndrome -subtype constipation according to rome iv criteria. * negative for colon cancer screening * negative relevant additional screening or consultation whenever appropriate. * ability of conforming to the study protocol. * stable treatment for parkinson's disease exclusion criteria: * presence of any other relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant on the basis of predefined values a part from parkinson's disease * ascertained intestinal organic diseases, including ascertained celiac disease or inflammatory bowel diseases (crohn's disease, ulcerative colitis, diverticular disease, infectious colitis, ischemic colitis, microscopic colitis). * previous major abdominal surgeries. * inability to conform with protocol. * recent history or suspicion of alcohol abuse or drug addiction. * previous participation in this study.

Keywords: constipation parkinson's disease
pressure-enabled retrograde occlusive therapy with embolization for control of thyroid disease (protect registry): a multicenter registry

Conditions: Hyperthyroidism; Goiter; Multinodular Goiter; Thyroid Nodules; Thyroid Disease; Hyperthyroidism; Toxic Multinodular Goiter

Summary: multi-center registry study to evaluate disease-related quality of life outcomes of thyroid embolization via pressure-enabled delivery (ped-tae). additional technical success data on parenchymal volume reduction, thyroid function tests changes and post-procedural complications will be recorded. data will be collected for patients who have undergone ped-tae using the trinav infusion system at participating sites. the registry study will include up to 10 sites, with sarasota memorial health care system acting as the lead site responsible for maintaining and monitoring the study database.


Eligibility criteria:
inclusion criteria: 1. adults, 18 years and older 2. having undergone ped-tae using the trinav infusion system 3. meeting one of the following criteria: 1. documented subclinical and or clinical hyperthyroidism in the presence of a toxic multinodular goiter or a toxic nodule \> 20 ml 2. patients' ineligible or refusing surgery, radio-iodine therapy or percutaneous ablation 3. non-functioning multinodular goiters or nodule causing compressive symptoms including but not limited to neck pain, dysphagia, stridor, exercise induced dyspnea and/or pressure symptoms 4. bethesda category 2-3 (benign, or atypia or follicular lesion of undetermined significance) on 2 separate fine-needle aspiration biopsy (fnab) results with a benign molecular profile with patient declining surgical resection exclusion criteria: 1. renal insufficiency 2. unable to tolerate angiography including pregnancy and severe allergy to contrast media 3. bethesda 4-6 on fnab (suspicious for follicular neoplasm, suspicious for malignancy, or malignant) 4. \<18 years old

Keywords: ped-tae trinav infusion system thyroid artery embolization
observational study of the effectiveness of funded drugs for genitourinary tumors.

Conditions: Genitourinary Cancers

Summary: sogug-princis is a retrospective (regarding patient inclusion) and prospective follow-up, epidemiological, non-interventional, non-blinded, non-randomized, multicenter, national observational study with drugs. this study will collect data from patients with genitourinary tumors to analyze the effectiveness under routine clinical practice conditions of drugs recently approved for funding in the spanish national health system. in all cases, the decision to start treatment will be made prior to and independently of participation in the study, which will be limited to subsequently collecting the data necessary to assess the objectives of the study. this study will serve as a registry for genitourinary cancers. every time a new drug will be authorized, a new subproject with a primary endpoint will be opened to recruitment. the substudy will try to validate with real-world data the endpoints reported in the phase iii clinical trials that led to the marketin authorization.


Eligibility criteria:
inclusion criteria: * patients ≥18 years old. * patients granting the icf unless exemption or exceptions mentioned below. * histological diagnosis of malignant neoplasia originating in the genitourinary system: kidney, renal pelvis, ureter, bladder, prostate, testicle and germinal tissue of other locations, urethra, penis, or seminal vesicles. * patients have started treatment with medications whose positive resolution of financing by the spanish national health system for the aforementioned tumors has been after january 1, 2023. * patients have started treatment after the official publication of the positive resolution of financing of the drug under study by the national health system. this restriction is intended to avoid interference of the study with the marketing authorization processes by the european medicines agency, and price and reimbursement negotiations by the spanish health authorities. * patients have received treatment at the participating center. exclusion criteria: * patients previously treated at another centre who have subsequently been referred to one of the participating centres. in this case, the patient will be included in the centre where treatment was started, or in the second centre if the first is not part of this study. * patients who do not meet any of the inclusion criteria. * evidence of an express objection by the subject or his/her legal representative to participate in the study.

Keywords: urothelial carcinoma prostate adenocarcinoma renal carcinoma darolutamida nivolumab enfortumab vedotin
a study to evaluate lu ag06466 in participants with fibromyalgia

Conditions: Fibromyalgia

Summary: the purpose of this study is to find out the effect of lu ag06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.

this study will include 2 treatment periods and will utilize a crossover study design with a 7- to 14-day washout period between each 22-day treatment period.

Eligibility criteria:
inclusion criteria: * the participant has a body mass index (bmi) of ≥18.5 and ≤38.0 kilograms (kg)/square meter (m\^2). * the participant has a fibromyalgia diagnosis, with self-reported pain visual analogue scale (vas) score \>4, based on a self-reported pain diary assessed for a minimum of 4 out of 7 days prior to the baseline visit. * the participant is, in the opinion of the investigator, eligible based on medical history, a physical examination, a neurological examination, vital signs (including orthostatic vital signs), an electrocardiogram (ecg), and the results of the clinical chemistry, hematology, urinalysis, serology, and other laboratory tests. exclusion criteria: * the participant has a disease, including clinically significant liver disease of any origin, or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. * the participant has any other disorder for which the treatment takes priority over the treatment of fibromyalgia in this study or is likely to interfere with the study treatment or impair treatment compliance. other inclusion and exclusion criteria may apply.
"effectiveness of community health workers in breast cancer prevention in jumla: a cluster randomized trials

Conditions: Breast Cancer; Prevention

Summary: breast cancer is the second most prevalent cancer among nepali females, accounting for 17.1% of cases and 7.7% of female cancer-related deaths. it is more common in younger, premenopausal women, often diagnosed at advanced stages. raising awareness through community education is crucial for promoting breast cancer screening, particularly in low-resource settings like nepal, where clinical breast exams are essential early detection tools. integrating breast cancer education into the health system can enhance knowledge, encourage screening, and promote healthy behaviors for prevention. early detection significantly improves treatment outcomes and survival rates. in remote areas, limited access to advanced detection technologies makes breast self-examination (bse) the most feasible and cost-effective method, particularly in jumla. this study evaluates the effectiveness of community health worker-led breast cancer prevention through health promotion and education strategies. it follows proctor's framework and the health belief model (hbm) a mixed-methods design will be employed, incorporating an embedded implementation science approach, a cluster-randomized trial, and mixed-method research. the study population includes married women of jumla, female community health volunteers (fchvs), and auxiliary nurse midwives (anms). exclusion criteria include married women ≥20 years old with existing cases of cancer, pregnant or lactating women, fchvs unable to acquire bse skills, and untrained anms. the sample consists of 90 participants in both intervention and control groups. acceptability, appropriateness, and feasibility will be assessed using the acceptability of intervention measure (aim) tool. sop-based checklists will evaluate fidelity, while fgds and kiis will collect qualitative data. quantitative data will be analyzed using frequency, percentage, mean, and standard deviation. a paired t-test and mixed-effect linear regression will assess effectiveness, while qualitative data will undergo thematic analysis. findings will be reported per consort guidelines. ethical approval will be obtained from the nepal health research council. expected outcomes include improved breast cancer knowledge, perception, and screening intention, leading to early detection and reduced prevalence. however, selection bias in cluster trials may limit generalizability.


Eligibility criteria:
inclusion criteria: * married women \>= 20 years of age group women of cnmp jumla, * fchv, those who can read, write, and understand, and * anm exclusion criteria: * married women \>= 20 years age group women who had a positive existing case, * pregnant and lactating women of cnmp jumla, * fchv those who cannot acquire the minimum skill of breast self-examination, * anm who untrained for bse.

Keywords: health promotion and education strategies
the effectiveness of itero element 5d niri system in early proximal caries detection in permanent teeth

Conditions: Dental Caries

Summary: as a new emerging technology for the diagnosis of dental caries, near-infrared imaging requires further research and validation to determine its effectiveness. this study aims to compare near-infrared imaging with cone-beam computed tomography (cbct) to validate the efficiency of near-infrared imaging in diagnosing proximal caries using large-scale clinical data through retrospective cross-sectional studies.


Eligibility criteria:
inclusion criteria: * permanent dentition * participants aged 12 and above * patients who have undergone itero element 5d oral scanning, as well as cbct imaging, intraoral photography, and clinical oral examination within 1 week * cbct or itero element 5d oral scanning indicating proximal caries exclusion criteria: the following teeth were excluded: * third molars * teeth with gross loss of tooth structure (cavitated carious lesions extending to the occlusal or buccal/lingual surfaces) * teeth with amalgam fillings and their adjacent teeth * teeth with crown restorations and their adjacent teeth
first in man study of the jenavalve tavi plus system transfemoral

Conditions: Aortic Valve Stenosis; Heart Valve Diseases; Heart Diseases; Cardiovascular Diseases

Summary: the objective of this study is to evaluate feasibility, safety and effectiveness of the first generation transfemoral jenavalve pericardial tavr system (formerly named jenavalve tavi plus system- transfemoral) in an elderly patient population with severe aortic stenosis who are at high risk for surgical aortic valve replacement.

the study is designed as a prospective, multi-center trial conducted at 2 centers in germany enrolling up to 12 subjects. each patient will be followed for 2 years. the last patient's follow-up will end in february 2016. it is planned that the study will end in june 2016. study endpoints are defined in accordance with the "standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the valve academic research consortium (varc-2)". these endpoint definitions combine the expertise of surgeons, interventionalists, medical cardiologists, clinical trial and other specialists and allow for comparison of different trials concerning effectiveness and safety in tavi.

Eligibility criteria:
inclusion criteria: * diagnosed with severe native aortic valve stenosis * nyha functional class ii or higher * increased risk for surgical aortic valve replacement * comply with post-operative follow-up visits and requirements exclusion criteria: * combined aortic valve disease with severe aortic insufficiency * presence of moderate mitral insufficiency or previous mitral prosthesis * severe pulmonary hypertension * congenital uni- or bicuspid aortic valve * endocarditis or active infection * life expectancy \< 12 months * need for emergency surgery for any reason

Keywords: aortic valve disease aortic valve replacement transcatheter transfemoral aortic stenosis
an investigational study of immunotherapy combinations with chemotherapy in patients with gastric or gastroesophageal junction (gej) cancers

Conditions: Gastric Cancer; Cancer of the Stomach; Esophagogastric Junction

Summary: the purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or gej cancer.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * histologically- or cytologically-confirmed diagnosis of unresectable and either locally advanced, or metastatic gastric cancer or gej adenocarcinoma * no prior treatment with systemic treatment (including her 2 inhibitors) given as primary therapy for unresectable and either locally advanced, or metastatic gc or gej adenocarcinoma * tumor tissue must be provided for biomarker analyses exclusion criteria: * participants with her2 positive status * participants with known untreated central nervous system (cns) metastases * uncontrolled or significant cardiovascular disease other protocol defined inclusion/exclusion criteria could apply
synergistic benefits of mce and bt in sacroiliac joint dysfunction: a randomized controlled trial

Conditions: Sacroiliac Joint Dysfunction

Summary: this research aimed to ascertain the combined and individual efficacies of mce and bt in alleviating sijd symptoms.

the study will be based on a four-arm parallel group randomized control design. one hundred and twenty participants with sijd will be recruited from the physiotherapy department, at integral university, india. study objectives and procedure will be properly explained and written informed consent will be obtained at the beginning of the study. all the participants will be randomly divided into four groups a, b, c, and d. experimental group a will be receiving the hot pack, stretching exercise, and mce intervention, group b will receive the hot pack, stretching exercise, and bt exercise and group c will be receiving the hot pack, stretching exercise, and mce \& bt intervention, control group d will receive the hot pack, stretching exercise intervention.

Eligibility criteria:
inclusion criteria: * age-30-60 years * sacroiliac joint pain (\>3 months) * presence of pain exacerbated as a result of bending laterally or backward * positive results on at least 2 of the pain-provocation tests \[faber, posterior shear and gaenslen pain provocation tests) and one of the motion palpation tests (ie, gillet and forward flexion tests) exclusion criteria: * past or current history of surgery or major trauma to spine, pelvis, lower limb, chest or abdomen in the past 12 months * lower extremity musculoskeletal disorders; known localized spinal pathology * known congenital anomalies of hip, pelvis or spine that limits mobility * known systematic arthropathy, neuropathy or metabolic disorder * presence of other causes of lbp such as lumbar discopathy and spinal stenosis discovered via clinical examination and mri scanning * pregnancy
omics-based precision medicine of epilepsy

Conditions: Epilepsy Idiopathic; Clinical Disease and/or Syndrome; Gene Mutation

Summary: epilepsy is a major disease of the nervous system (who, 2015), as well as the second most common neural disease. it has been recorded that there have been 65 million epilepsy patients all over the world, more than 10 million in china, resulted in high morbidity, high mortality, heavy social and social psychological burden. due to complex etiology, which genetic playing a large part for 70%-80%, easy to recurrent, as well as various seizure types, a great heterogeneity in clinical manifestation, epilepsy is difficult to treat in general, at least 33% patients. at present, it's still a big challenge in early warning, choice of treatment, efficacy and severe adverse reaction rate, prognosis assessment. lack of precise diagnosis based genetic and molecular bio-markers for treatment are the main key points. recently, clinical phenotype classifications of epilepsy have been refined, the exist researches had made a progress in gene mutation mechanism and targeted therapy, which pushed epilepsy being another disease could be precise treated after tumor. it's sure to provide a breakthrough for another neural diseases if epilepsy precise treatment project are successful.

research projects: part 1: based on already existed large samples of epilepsy clinical cases, choose 2,0000 non-acquired epilepsy patients for clinical general phenotype and middle phenotype(eeg and mri) data collection to further multi-dimensional standardization measure and evaluate. through metabolic detection to define micro-phenotype. establish a standardized clinical and biological samples database. part 2: by ngs technology to sequence for all cases, including family members, then require genotype. to test brain tissue dna somatic mutation, which mri negative and had an operation. to verify the newly discovered pathogenic candidate genes and carry on functional studies. finally, to draw epileptic genetic mutations mapping in chinese people. part 3: integrated clinical and genetic epilepsy phenotypic data, combined with neural eeg and image bitmap data points for bio-markers analysis, included early warning, classification of diagnosis, curative effect prediction and epilepsy con-morbidity disease.

Eligibility criteria:
inclusion criteria: * non-acquired epilepsy; family involved(children, father and mother); han nationality; consent and will to follow up exclusion criteria: * acquired epilepsy; very low birth weight infant

Keywords: phenotype; genotype
a study to determine optimal absorption of single dose omega-3

Conditions: Optimal Gastrointestinal Absorption of Omega-3

Summary: this is a randomised three-way cross over study comparing the optimal absorption of a single dose of fish oil using 3 different forms to one another on increasing blood concentrations of fatty acids in 24 healthy adult participants aged 19 years and over.


Eligibility criteria:
inclusion criteria: * male and females over 19 years and otherwise healthy * healthy bmi \&gt;18.0 and \&lt;30.0 * able to provide informed consent * agree to arrive fasted on the day of the trial * agree to participate in all arms of the study exclusion criteria: * unstable or serious illness \[e.g. kidney, liver (including nafld), git, heart conditions, diabetes, thyroid gland function malignancy\]\* * any treatment that included radiation or chemotherapy within the previous 2 years * receiving/prescribed coumandin (warfarin), heparin, daltaparin, enoxaparin or other anticoagulation therapy. * regular use of supplements containing the investigational material (e.g. omega-3 fatty acids), in the last 3 months, regular consumption of foods containing the investigational material (e.g. fish for omega-3) # * active smokers, nicotine, alcohol, drug abuse * chronic past and/or current alcohol use (\&gt;14 alcoholic drinks week) * allergic to any of the ingredients (i.e., fish oil) * pregnant or lactating women * any condition which in the opinion of the investigator makes the participant unsuitable for inclusion * an unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. a serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments. * regular use or consumption is considered if participants are consuming omega containing supplements or foods on 3 or more days per week.
opioid and cannabinoid interactions

Conditions: Marijuana Usage; Opioid Use

Summary: this study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. the primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.


Eligibility criteria:
inclusion criteria: * healthy adults ages 18-50 * current non-medical use of opioids and marijuana exclusion criteria: * physical dependence on opioids, alcohol benzodiazepines/sedative/hypnotics * seeking treatment for drug use * significant medical problems

Keywords: marijuana opioid opiate cannabis